Table 2.
Cases of hypopigmented mycosis fungoides concomitant with other MF variants. Cases published up to March 2020.
| Study | Number of Patients | Age of Onset (years) | Fitzpatrick Phototype/Color of Skin/ Ethnicity | Other Variants of MF as Published | Stage at Diagnosis | Disease Progressed |
|---|---|---|---|---|---|---|
| Sigal et al., 1987 [79] | 1 | 64 | White | Erythematous papules | NS a | Yes a |
| el-Hoshy and Hashimoto, 1995 [104] | 1 | 15 | Black | Erythematous nodules | NS | No |
| Lambroza et al., 1995 [84] | 1 | 21 | Jamaican-American | Hyperpigmented | IB | No |
| Qari et al., 2000 [88] | 3 | 25.3 (mean) | Hispanic/dark and Portuguese/black | Red papules, pink patches, erythematous, and scaly plaques | NS | No |
| Stone et al., 2000 [80] | 1 | 56 | Type V | Hyperpigmented macules later evolved to erythematous lesions | I | Yes b |
| Ardigo et al., 2003 [16] | 6 | 30.1 (mean) | Caucasian | Erythematous lesions | NS | 2 patients c |
| Ben-Amitai et al., 2003 [105] | 5 | 4.6 (mean) | Light and pigmented | Classic erythematous lesions | IA: 2 patients IB: 3 patients |
No |
| Wain et al., 2003 [75] | 2 | 10.5 (mean) | NS | Poikiloderma and pilotropic | IB | No |
| Hodak et al., 2005 [90] | 2 | 1 (mean) | NS | Psoriasiform | IB and IA | 1 patient (IIA) |
| Wain et al., 2005 [91] | 2 | 21.5 (mean) | Asian and Somalian | Poikiloderma and hyperpigmented | IA and IB | No |
| Hodak et al., 2006 [48] | 1 | 12 (at diagnosis) | NS | Classic | IB | No |
| Hsiao et al., 2006 [106] | 1 | 12 | NS | Hyperpigmented | IA | No |
| Onsun et al., 2006 [92] | 1 | 5 (mean) | Type II: 1 patient Type III: 1 patient |
Erythematous | IB | No |
| Ozcan et al., 2008 [107] | 1 | 30 | Turkish | Erythematous | NS | NS |
| Cho-Vega et al., 2010 [108] | 1 | 34 | African-American | Poikiloderma | IB | No |
| Nanda et al., 2010 [109] | 3 | 7.5 (mean) | Bedouin and Kuwaiti | Pityriasis lichenoides chronica-like and folliculotropic | IA, IB, and IIA | NS |
| Khopkar et al., 2011 [110] | 5 | 19 (mean) | Asian with dark skin type | Poikiloderma and erythematous | NS d | NS d |
| Yazganoglu et al., 2013 [74] | 8 | 6.1 (mean) | NS | Erythematous and purpuric | IA: 5 patients IB: 3 patients |
No |
| Rizzo et al., 2012 [111] | 1 | 15 (at diagnosis) | NS | Erythematous | IB | NS |
| Uhlenhake and Mehregan, 2012 [112] | 1 | 49 | African-American | Hypopigmented macules with hyperpigmented/erythematous centers | NS | NS |
| Wongpraparut and Setabutra, 2012 [113] | 1 | 36 | Type IV | Erythematous | IA | No |
| Ahumidi, 2014 [97] | 1 | 5 | Type III e | Pink papules | NS | NS |
| Furlan et al., 2014 [83] | 14 | 29.5 (median) | Mixed race, Caucasian, Black, and Asian/Brazilian | Erythematous, poikiloderma, hyperpigmented, purpuric, and hyperkeratotic | IA: 7 patients IB: 6 patients IIA: 1 patient |
NS |
| Gameiro et al., 2014 [114] | 1 | 5 | Type III | Erythematous papules | IB | No |
| Heng et al., 2014 [115] | 11 | NS | Chinese, Malay, Indian, and others | Red, scaly papules and plaques | NS | NS |
| Fatemi Naeini et al., 2015 [116] | 2 | NS | Iranian | NS | NS | NS |
| Naeini et al., 2015 [117] | 1 | 26 | Iranian | Erythematous | IB | NS |
| Ichimura et al., 2016 [118] | 1 | 20 | Japanese | Scaly erythema | IB | No |
| Cervini et al., 2017 [76] | 2 | 11 (mean at diagnosis) | Argentinian | Classic MF | IVA2f and IB | No |
| Pradhan et al., 2017 [81] | 1 | 2 | Iranian | Large cell transformation | IB | No |
| Landgrave-Gomez et al., 2019 [103] | NS | NS | Hispanic | Hyperpigmentation and erythema | NS | NS |
| Valencia Ocampo et al., 2019 [119] | 5 | 7.8 (mean) | Type II: 1 patient Type III: 1 patient Type IV: 2 patients Type V: 1 patient |
Erythematous | IA: 1 patient IB: 4 patients |
No |
| Geller et al., 2019 [82] | 34 | NS | African-American | Erythematous and hyperpigmented | NS | No |
| Kalay et al., 2020 [120] | 4 | 30.5 (mean at diagnosis) | Turkish | Follicular hyperkeratosis, erythematous, and hyperpigmented | IA | No |
NS, not specified. a Staging not specified. However, since the initial diagnosis, the patient presented with lymph node involvement and after 2 years, the patient died of septicemia and bone marrow aplasia. b Disease progression to another stage not specified. After 2 years, the patient presented with erythematous plaques, nodules, and tumors and the authors suspected lymphomatous spread from MF. The patient died of acute respiratory distress syndrome. c Progressive disease, but no new stage mentioned. d The authors mentioned that patients did not show lymph enlargement or visceral involvement and remained with same clinical characteristics. e The authors did not report phototype for each patient. However, the authors mentioned that Saudi Arabian individuals are mostly skin phototype III–IV. f Lymph node involvement documented. However, this patient had a follow up of 7.5 years and remained disease-free for 4 years without progression.